Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 86

    Lindsay Goldberg to buy Bilcare Research in a deal worth USD 279-334 million: Report

    Lindsay Goldberg to buy Bilcare Research in a deal worth USD 279-334 million: Report

    Medical Dialogues Bureau5 Sept 2019 9:00 AM IST
    Bilcare Research, which employs 1000 staff and has annual sales of 300 million euros, produces plastic packaging used in the pharmaceutical, consumer...
    Lupin, Boehringer Ingelheim sign USD 700 million deal for novel oncology drug

    Lupin, Boehringer Ingelheim sign USD 700 million deal for novel oncology drug

    Farhat Nasim4 Sept 2019 5:00 PM IST
    Lupin will receive an upfront payment of $20 million and potential additional payments for successful achievement of defined clinical, regulatory and...
    Sandoz to commercialize biosimilar of MS drug Natalizumab

    Sandoz to commercialize biosimilar of MS drug Natalizumab

    Medical Dialogues Bureau4 Sept 2019 9:45 AM IST
    Under the agreement, Sandoz will commercialize and distribute natalizumab biosimilar in all markets upon approval, through an exclusive global...
    Former JnJ executive Marianne De Backer to lead Bayer pharma division

    Former JnJ executive Marianne De Backer to lead Bayer pharma division

    Medical Dialogues Bureau4 Sept 2019 9:30 AM IST
    Marianne De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival JnJ,...
    Vertex Pharma, Semma enter deal worth USD 950 million to develop treatments for diabetes

    Vertex Pharma, Semma enter deal worth USD 950 million to develop treatments for diabetes

    Medical Dialogues Bureau4 Sept 2019 9:15 AM IST
    The deal represents Vertex Pharma's foray into a new treatment space, as the company typically develops treatments for cystic fibrosis, an inherited...
    Purdue Pharma prepares free-fall bankruptcy as settlement talks halt: Report

    Purdue Pharma prepares free-fall bankruptcy as settlement talks halt: Report

    Medical Dialogues Bureau4 Sept 2019 9:00 AM IST
    U.S: OxyContin maker Purdue Pharma LP is preparing to seek bankruptcy protection before the end of the month if it does not reach a settlement with...
    Zydus Cadila wins DCGI nod for marketing rabies drug Twinrab

    Zydus Cadila wins DCGI nod for marketing rabies drug Twinrab

    Medical Dialogues Bureau3 Sept 2019 10:00 AM IST
    "The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure...
    Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals

    Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals

    Medical Dialogues Bureau3 Sept 2019 9:30 AM IST
    Novartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of...
    Roche Xofluza shows promise in reducing risk of developing flu by 86pc

    Roche Xofluza shows promise in reducing risk of developing flu by 86pc

    Medical Dialogues Bureau3 Sept 2019 9:05 AM IST
    "Xofluza is the first and only one-dose oral medicine approved to treat flu in otherwise healthy patients, and the first new flu medicine with a novel...
    China expansion of drug bulk-buy programme puts pressure on pharma companies

    China expansion of drug bulk-buy programme puts pressure on pharma companies

    Medical Dialogues Bureau3 Sept 2019 9:00 AM IST
    The programme rolled out last year saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process to bulk-buy 25 types...
    Sanofi revival depends on outsider with nose for big drugs: Report

    Sanofi revival depends on outsider with nose for big drugs: Report

    Medical Dialogues Bureau3 Sept 2019 8:58 AM IST
    Defining Sanofi's ambitions in the cutting-edge field of gene therapies and figuring out whether to hold on to consumer health brands are among other...
    Fund Diversion Case: SEBI restricts Transgene Biotek, 6 others from securities market

    Fund Diversion Case: SEBI restricts Transgene Biotek, 6 others from securities market

    Medical Dialogues Bureau2 Sept 2019 10:00 AM IST
    Besides, Transgene will continue the measures to recall the outstanding amount of USD 38.5 million and bring the money back into its bank account in...
    PrevNext

    Popular Stories

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

    FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

    Suven Life Sciences Q2 revenue up 39pc to Rs 280 crore

    Suven Life Sciences Q2 revenue up 39pc to Rs 280 crore

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    MEDICREA UNiD IB3D Patient-Matched interbody cages get USFDA clearance

    MEDICREA UNiD IB3D Patient-Matched interbody cages get USFDA clearance

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Ministry of AYUSH invites initial bids for strategic sale of IMPCL

    Ministry of AYUSH invites initial bids for strategic sale of IMPCL

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok